Search Results

FDA Advisory Committee Supports Donanemab in Alzheimer's Disease.

• Authors : Myshko, Denise

Subjects: THERAPEUTIC use of monoclonal antibodies; ALZHEIMER'S disease; PATIENT safety

• Source: Formulary Watch. 6/11/2024, p1-1. 1p.

Record details

FDA to hold Advisory Committee on Donanemab in Alzheimer's Disease.

• Authors : Myshko, Denise

Subjects: TAU proteins; ALZHEIMER'S disease; MEETINGS

• Source: Formulary Watch. 3/8/2024, p2-2. 1p.

Record details

FDA Sets Advisory Meeting for Abecma in Supplemental Multiple Myeloma Indication.

Subjects: MEETINGS; DISEASE progression; NEUROTOXICOLOGY

• Source: Formulary Watch. 2/5/2024, p1-1. 1p.

Record details

FDA’s ODAC Finds Cilta-Cel Favorable in R/R Multiple Myeloma.

• Authors : Sava, Jordyn

Subjects: MULTIPLE myeloma; CANCER relapse; PATIENT safetyUNITED States. Food & Drug Administration

• Source: Targeted Therapies in Oncology; Apr2024, Vol. 13 Issue 5, p19-21, 3p

Record details

The New Mexico Nursing Education Consortium: Fostering Innovative Education to Promote Health Equity.

• Authors : Liesveld, Judy

Subjects: DISEASE progression; EVALUATION of medical care; EVALUATION of human services programsNEW Mexico

• Source: Nursing Administration Quarterly; Jul-Sep2022, Vol. 46 Issue 3, p218-223, 6p

Record details

Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy.

• Authors : Capdevila, Jaume; Grande, Enrique; García-Carbonero, Rocío

Subjects: GASTROINTESTINAL tumors treatment; CONSENSUS (Social sciences); DISEASE progression

• Source: Oncologist; Apr2022, Vol. 27 Issue 4, pe328-e339, 12p, 4 Charts

Record details

重组腺病毒介导神经生长因子转染实验性自身免疫性脑脊髓炎模型小鼠 少突胶质细胞的凋亡及髓鞘化.

• Authors : 谢 阳; 吕志宇; 张淑江

Subjects: NERVE growth factor; MYELIN basic protein; MYELIN proteins

• Source: Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu; 8/18/2021, Vol. 25 Issue 23, p3678-3683, 6p

Record details

FDA Committee Agrees That MRD Is a Viable End Point in Myeloma Trials.

• Authors : Serani, Sabrina

Subjects: MULTIPLE myeloma; CLINICAL trials; CARCINOGENESISUNITED States. Food & Drug Administration

• Source: Targeted Therapies in Oncology; Jun2024, Vol. 13 Issue 7, p14-15, 2p

Record details

Assessment of gastric emptying half time as a quantitative measure of gastrointestinal dysmotility in systemic sclerosis.

• Authors : Adarsh, M. B¹; Bhattacharya, Anish²; Sharma, Shefali K¹

Subjects: *CONSENSUS (Social sciences); *ETHICS committees; *GASTROINTESTINAL motility

• Source: Rheumatology. Nov2019, Vol. 58 Issue 11, p2064-2065. 2p. 1 Chart.

Record details

FDA Advisory Committee Votes Down Pepaxto for Multiple Myeloma.

• Authors : Myshko, Denise

Subjects: DRUG approval; DISEASE progression; COMMITTEES

• Source: Formulary Watch. 9/24/2022, p1-1. 1p.

Record details